The vaccine does not prevent gonorrhoea despite 30,000 people already vaccinated
A clinical trial in Australia has quietly dismantled the scientific rationale behind a vaccination programme that England's NHS launched just months ago. Researchers found that the Meningitis B vaccine, offered to gay and bisexual men on the strength of earlier promising data, provides no meaningful protection against gonorrhoea — a disease already straining public health systems with record case numbers and growing antibiotic resistance. The episode places health authorities in the uncomfortable position of having acted in good faith on incomplete evidence, and now facing the harder task of acknowledging what the fuller picture reveals.
- A two-year Australian trial of 587 men found virtually identical gonorrhoea infection rates in vaccinated and placebo groups, delivering a direct blow to the vaccine's credibility as a prevention tool.
- Over 30,000 people in England have already begun a vaccination course whose core justification has now been publicly undermined by the very type of rigorous evidence it was always waiting for.
- The UK Health Security Agency has stopped short of pausing the programme, offering instead a measured wait-and-see response that critics argue is inadequate given the weight of new evidence.
- Sexual health advocates are pressing the Joint Committee on Vaccination and Immunisation to formally reassess the strategy, while reminding the public that condoms and regular testing remain the most dependable defences.
- Gonorrhoea cases in England, though slightly down from a 2022 peak, remain double the rate of a decade ago, and antibiotic-resistant strains are making the absence of an effective vaccine increasingly consequential.
A large clinical trial in Australia has thrown into doubt a vaccination campaign that the NHS launched across England just months ago. The GoGoVax study, published in the New England Journal of Medicine, followed 587 men over two years and found no meaningful difference in gonorrhoea infection rates between those who received the Meningitis B vaccine and those given a placebo — 291 infections in the vaccinated group, 285 in the control. The authors concluded that their findings, aligned with two other recent trials, constituted strong evidence the vaccine does not work for gonorrhoea prevention.
The logic behind the original hope was biological: the bacteria causing meningitis B and gonorrhoea are closely related, raising the possibility of cross-protection. Earlier studies had reported a 38 percent reduction in infections, enough to persuade British health authorities to begin offering the jab to gay and bisexual men last August. More than 30,000 people in England have since started the course.
The UK Health Security Agency has not moved to halt the programme. Its director of public health programmes indicated the agency was weighing a range of evidence and would eventually draw on data from England's own rollout — a posture that some experts consider insufficient given the clarity of the new findings. Taku Mukiwa of the Terrence Higgins Trust called on the Joint Committee on Vaccination and Immunisation to reconsider the programme, stressing that condoms and regular testing remain the most reliable prevention tools available.
Gonorrhoea continues to pose a serious challenge in Britain, with case numbers still double those of a decade ago and antibiotic-resistant strains complicating treatment. Researchers remain committed to finding an effective vaccine, but the GoGoVax results have forced an honest reckoning with the gap between early promise and definitive proof — and with the cost of acting before that proof arrives.
A large clinical trial in Australia has upended the logic behind a vaccination campaign that began rolling out across England just months ago. The Meningitis B vaccine, which the NHS started offering to gay and bisexual men last August, does not actually prevent gonorrhoea infections, according to research published this week in the New England Journal of Medicine. The finding contradicts earlier studies that had suggested the vaccine might offer protection against the sexually transmitted infection, and it raises hard questions about a public health decision made on incomplete evidence.
The trial, called GoGoVax, followed 587 men over two years. Researchers at the University of New South Wales divided participants into two groups: one received the actual MenB vaccine, the other a placebo. The results were stark in their symmetry. Among the vaccinated men, 291 developed new gonorrhoea infections. Among those given the placebo, 285 did. The difference was not statistically significant. The study's authors concluded their findings aligned with two other recent trials, and together these three studies provided what they called "strong evidence that the MenB vaccine is not effective for gonorrhea prevention."
The vaccine in question was originally designed to protect infants against meningitis B. The bacteria responsible for meningitis and the bacteria that causes gonorrhoea are closely related, which is why researchers had theorized the vaccine might offer cross-protection. Earlier studies had reported a 38 percent reduction in gonorrhoea infections among vaccinated men, a finding that persuaded British health authorities to begin offering the jab to at-risk populations. Since August 2025, over 30,000 people in England have started the vaccination course based on that promise.
The UK Health Security Agency has not yet recommended halting the programme. Dr Mary Ramsay, the agency's director of public health programmes, said the organisation was considering "a range of evidence" and that the data from England's own vaccination rollout would eventually provide "more robust data on vaccine impact and effectiveness." That statement amounts to a wait-and-see posture at a moment when clarity is needed. The agency has not committed to publishing its findings on any particular timeline.
Gonorrhoea remains a stubborn public health problem in Britain. Cases peaked at 82,592 in 2022, fell to 63,943 by 2025, but remain double the rate from a decade earlier. Gay and bisexual men bear a disproportionate burden of infection, according to the European Centre for Disease Prevention and Control. The emergence of antibiotic-resistant strains has made treatment increasingly difficult, raising the stakes for prevention.
Experts have called the Australian trial results disappointing but not cause for despair. Dr Odile Harrison, an infectious disease epidemiologist at Oxford, said the findings should not discourage the search for an effective gonorrhoea vaccine, which remains a global priority. Taku Mukiwa, head of health programmes at the Terrence Higgins Trust, a sexual health charity, was more direct. He argued that the Joint Committee on Vaccination and Immunisation should reconsider the programme now that the evidence has shifted. He emphasised that condoms and regular testing remain the most reliable tools for prevention and stopping transmission.
The episode illustrates a familiar tension in public health: the pressure to act on promising preliminary data versus the need to wait for definitive proof. The NHS moved forward with the vaccine rollout in good faith, based on what seemed like encouraging evidence. But the larger Australian trial has now cast doubt on that evidence. The question now is whether health authorities will acknowledge the shift quickly enough to prevent further investment in a strategy that may not work.
Citações Notáveis
If the evidence has changed, the approach has to change too.— Taku Mukiwa, Terrence Higgins Trust
Gonorrhoea remains a major global public health threat, particularly with the continued emergence of antimicrobial resistance, and an effective vaccine remains a high priority.— Dr Odile Harrison, University of Oxford
A Conversa do Hearth Outra perspectiva sobre a história
Why did the NHS roll out this vaccine if the evidence wasn't solid?
The earlier studies looked promising—they suggested a 38 percent reduction in infections. In public health, you sometimes have to move on the best data available at the time. But this Australian trial was much larger and more rigorous, and it found nothing.
So 30,000 people got vaccinated for no reason?
Not quite. We don't know yet if those vaccinations are useless—the UK's own data from those 30,000 people might tell a different story. But yes, there's a real possibility they received a vaccine based on evidence that didn't hold up.
Why would earlier studies show protection if it doesn't actually exist?
That's the hard question. It could be statistical chance, or the earlier studies might have had methodological differences. The Australian trial was designed specifically to test this, with a placebo control and careful monitoring over two years.
What do people do now instead?
Condoms and regular testing. Those are the proven tools. They're not as clean a solution as a vaccine would be—they require ongoing behaviour change—but they work.
Is this the end of looking for a gonorrhoea vaccine?
No. Experts say the search continues because the problem is real and getting worse, especially with antibiotic resistance. But this trial shows you can't cut corners on evidence, even when you're trying to help.